AR031852A1 - Compuestos para tratar enfermedad de alzheimer - Google Patents

Compuestos para tratar enfermedad de alzheimer

Info

Publication number
AR031852A1
AR031852A1 ARP010103113A ARP010103113A AR031852A1 AR 031852 A1 AR031852 A1 AR 031852A1 AR P010103113 A ARP010103113 A AR P010103113A AR P010103113 A ARP010103113 A AR P010103113A AR 031852 A1 AR031852 A1 AR 031852A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
optionally substituted
alkoxy
csn
Prior art date
Application number
ARP010103113A
Other languages
English (en)
Original Assignee
Elan Pharm Inc
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Upjohn Co filed Critical Elan Pharm Inc
Publication of AR031852A1 publication Critical patent/AR031852A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/22—Hydrazines having nitrogen atoms of hydrazine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invencion comprende una amina sustituida de la formula (1)en donde R1 es (I) C1-6alquilo, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de C1-3alquilo, C1-7 alquilo (opcionalmente sustituido con C1-3 alquilo y C1-3 alcoxi), -F, -Cl, -Br, -I, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, -OC=O NR1-aR1-b en donde R1-a y R1b son como se ha definido anteriormente, (II) ûCH2-S(O)0-2(C1-6 alquilo), (III) ûCH2-CH2-S(O)0-2-(C1-6alquilo), (IV) C2-6 alquenilo con uno o dos enlaces dobles, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (V) C2-6 alquinilo con uno o dos enlaces triples, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, -CF3, C1-3alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (VI) û(CH2)n1-(R1-arilo) en donde n1 es cero o uno y en donde R1-arilo es fenilo, 1-naftilo, 2-naftilo e indanilo, indenilo, dihidronaftalilo, tetralinilo, opcionalmente sustituido con uno, dos, tres o cuatro de los siguientes sustituyentes en el anillo arilo: (A) C1-6 alquilo opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de C1-3 alquilo, -F, Cl, -Br, -I, -OH, -SH, -NR1-aR1-b en donde R1-a y R1-b son como se definio anteriormente, -CsN, -CF3, C1-3 alcoxi, (B) C2-6 alquenilo con uno o dos enlaces dobles opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (C)C2-6 alquinilo con uno o dos enlaces triples, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (D) ûF, -Cl, -Br y ûI, (F)-C1-6 alcoxi opcionalmente sustituido con uno, dos o tres de ûF, (G) ûNRN-2RN-3 donde RN-2 y RN-3 son como se ha definido anteriormente, (H) ûOH (I) ûCsN, (J) C3-7 cicloalquilo, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son -H o C1-6 alquilo, (K) ûCO-(C1-4 alquilo) , (L) ûSO2NR1-aR1-b en donde R1-a y R1-b son como se ha definido anteriormente, (M) ûCO-NR1-aR1-b en donde R1-a y R1-b son como se ha definido anteriormente, (N) ûSO2-(C1-4 alquilo), (VII)-(CH2)n1-(R1-heteroarilo) en donde n1 es como se definio anteriormente y en donde R1-heteroarilo está seleccionado del grupo que consiste de: (A) piridinilo, (B) pirimidinilo, (C) quinolinilo, (F) benzotienilo, (G) indolilo, (H) indolinilo, (I) piridazinilo, (J) pirazinilo, (K) isoindolilo, (L) isoquinolilo, (M) quinazolinilo, (N) quinoxalinilo, (O) ftalazinilo, (P) imidazolilo, (Q) isoxazolilo, (R) pirazolilo, (S) oxazolilo, (T) tiazolilo, (U) indolizinilo, (V) indazolilo, (W) benzotiazolilo, (X) bencimidazolilo, (Y) benzofuranilo, (Z) furanilo, (AA) tienilo, (BB) pirrolilo, (CC) oxadiazolilo, (DD) tiadiazolilo, (EE) triazolilo, (FF) tetrazolilo, (II) oxazolopiridinilo, (JJ) imidazopiridinilo, (KK) isotiazolilo, (LL) naftiridinilo, (MM) cinnolinilo, (NN) carbazolilo, (OO) beta-carbolinilo, (PP) isocromanilo, (QQ) cromanilo, (SS) tetrahidroisoquinolinilo, (TT) isoindolinilo, (UU) isobenzotetrahidrofuranilo, (VV) isobenzotetrahidrotienilo, (WW) isobenzotienilo, (XX) benzoxazolilo, (YY) piridopiridinilo, (ZZ) benzotetrahidrofuranilo, (AAA) benzotetrahidrotienilo, (BBB) purinilo, (CCC) benzodioxolilo, triazinilo, fenoxazinilo, fenotiazinilo, pteridinilo, benzotiazolilo, imidazopiridinilo, imidazotiazolilo, dihidrobencisoxazinilo, bencisoxazinilo, benzoxazinilo, dihidrobencisotiazinilo, benzopiranilo, benzotiopiranilo, cumarinilo, isocumarinilo, cromonilo, cromanonilo, piridinil-N-oxido donde el grupo R1-heteroarilo está ligado al û(CH2)n1-mediante cualquier átomo del anillo del grupo madre RN-heteroarilo sustituido por hidrogeno de modo que el nuevo enlace al grupo R1-heteroarilo reemplaza el átomo de hidrogeno y su enlace, en donde el heteroarilo está opcionalmente sustituido con uno, dos tres o cuatro: (1) C1-6 alquilo opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de C1-3 alquilo, -F, -Cl, -Br, -I, -OH, -SH, -NR1-aR1-b en donde R1-a y R1-b son como se definio anteriormente, -CsN, CF3, C1-3 alcoxi, (2) C2-6 alquenilo con uno o dos enlaces dobles opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (3) C2-6 alquinilo con uno o dos enlaces triples, opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (4) ûF, -Cl, -Br y ûI, (6)-C1-6 alcoxi opcionalmente sustituido con uno, dos o tres de ûF, (7) ûNRN-2RN-3 donde RN-2 y RN-3 son como se define más adelante, (8) ûOH, (9) ûCsN, (10) C3-3 cicloalquilo, opcionalmente sustituido con uno dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde NR1-aR1-b son ûH o C1-6 alquilo, (11) ûCO-(C1-4 alquilo), (12)-SO2-NR-NR1-aR1-b donde R1-a y R1-b son como se definio anteriormente, (13)-CO-NR1-aR1-b donde R1-a y R1-b son como se definio anteriormente, (14) ûSO2-(C1-4 alquilo), con la condicion de que cuando n1 es cero, R1-heteroarilo no está ligado a la cadena de carbonos mediante el nitrogeno, (VIII) û(CH2)n1-(R1-heterociclo) donde n1 es como se definio anteriormente y R1-heterociclo está seleccionado del grupo que consiste de: (A) morfolinilo, (B) tiomorfolinilo, (C) tiomorfolinil S-oxido, (D) tiomorfilinil S,S-dioxido, (E) piperazinilo, (F) homopiperazinilo, (G) pirrolidinilo, (H) pirrolinilo, (I) tetrahidropiranilo, (J) piperidinilo, (K) tetrahidrofuranilo, (L) tetrahidrotienilo, (M) homopiperidinilo, homomorfolinilo, homotiomorfolinilo, homotiomorfolinil S-oxido, homotiomorfolinil S,S-dioxido, y oxazolidinonilo, donde el grupo R1-heterociclo está ligado mediante cualquier átomo del grupo madre R1-heterociclo sustituido por hidrogeno de modo tal que el nuevo enlace al grupo R1-heterociclo reemplaza el átomo de hidrogeno y su enlace, en donde el heterociclo está opcionalmente sustituido con uno, dos tres o cuatro: (1) C1-6 alquilo opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de C1-3 alquilo, -F, -Cl, -Br, -I, -OH, -SH, -NR1-aR1-b en donde R1-a y R1-b son como se definio anteriormente, -CsN, -CF3, C1-3 alcoxi (2) C2-6 alquenilo con uno o dos enlaces dobles, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (3) C2-6 alquinilo con uno o dos enlaces triples, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (4) ûF, -Cl, -Br y ûI, (5) C1-6 alcoxi, (6) ûC1-6 alcoxi opcionalmente sustituido con uno, dos o tres ûF, (7) ûNRN-2RN-3 en donde RN-2 y RN-3 son como se define más adelante, (8) ûOH, (9) ûCsN, (10) C3-7 cicloalquilo, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH, o C1-6 alquilo, (11) ûCO(C1-4 alquilo), (12) ûSO2-NR1-aR1-b en donde R1-a y R1-b son como se definio anteriormente, (13) ûCO-NR1-aR1-b en donde R1-a y R1-b son como se definio anteriormente, (14) ûSO2-(C1-4alquilo), (15) =O, con la condicion de que cuando n1 es cero R1-heterociclo no está ligado a la cadena de carbono mediante nitrogeno; en donde R2 está seleccionado del grupo consistente de (I) ûH, (II) C1-6 alquilo, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de C1-3 alquilo, -F, -Cl, Br, -I, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son como se definio anteriormente; (III) û(CH2)0-4-R2-1 en donde R2-1 es R1-arilo o R1-heteroarilo en donde R1-arilo y R1-heteroarilo son como se definio anteriormente ; (IV) C2-6 alquenilo con uno o dos enlaces, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (V) C2-6 alquinilo con uno o dos enlaces triples, opcionalmente sustituido con uno, dos o tres sustituyentes del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, (VI) û(CH2)0-4-C3-7 cicloalquilo, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de ûF, -Cl, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-a y R1-b son ûH o C1-6 alquilo, donde R3 está seleccionado del grupo que consiste de: (I) ûH, (II) C1-6 alquilo, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de C1-3 alquilo, -F, -Cl, -Br, -I, -OH, -SH, -CsN, -CF3, C1-3 alcoxi, -NR1-aR1-b en donde R1-aR1-b en donde R1-a y R1-b son como se define anteriormente, (III) û(CH2)0-4-R2-1 en donde R2-1 es R1-arilo o R1-heteroarilo en donde R1-arilo y R1-heteroarilo son como se definio anteriormente; (IV) C2-6 alquenilo con uno o dos enlaces dobles, (V) C2-6 alquinilo con uno o dos enlaces triples, (VI) û(CH2)0-4-C3-7 cicloalquilo, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste d
ARP010103113A 2000-06-30 2001-06-29 Compuestos para tratar enfermedad de alzheimer AR031852A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21532300P 2000-06-30 2000-06-30
US25273600P 2000-11-22 2000-11-22
US25595600P 2000-12-15 2000-12-15
US26849701P 2001-02-13 2001-02-13
US27977901P 2001-03-29 2001-03-29
US29558901P 2001-06-04 2001-06-04

Publications (1)

Publication Number Publication Date
AR031852A1 true AR031852A1 (es) 2003-10-08

Family

ID=27559082

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103113A AR031852A1 (es) 2000-06-30 2001-06-29 Compuestos para tratar enfermedad de alzheimer

Country Status (22)

Country Link
US (1) US7214715B2 (es)
EP (1) EP1353898A2 (es)
JP (1) JP2004502669A (es)
KR (1) KR20030058960A (es)
CN (1) CN100366605C (es)
AR (1) AR031852A1 (es)
AU (1) AU2001273137A1 (es)
BR (1) BR0112000A (es)
CA (1) CA2410651A1 (es)
CZ (1) CZ20024194A3 (es)
EA (1) EA007337B1 (es)
EE (1) EE200200716A (es)
HU (1) HUP0303037A3 (es)
IL (1) IL153214A0 (es)
MX (1) MXPA02012608A (es)
NO (1) NO20026199L (es)
NZ (3) NZ547529A (es)
PE (1) PE20020276A1 (es)
PL (1) PL359864A1 (es)
SK (1) SK18442002A3 (es)
UY (1) UY26813A1 (es)
WO (1) WO2002002512A2 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502664A (ja) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
CA2417127A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
AR035960A1 (es) 2001-04-23 2004-07-28 Elan Pharm Inc Epoxidos sustituidos y procesos para prepararlos
BR0210721A (pt) 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
CN101068772A (zh) * 2001-07-11 2007-11-07 艾伦药物公司 N－(3－氨基－2－羟基－丙基)取代烷基酰胺化合物
EP1443923A1 (en) * 2001-10-29 2004-08-11 Elan Pharmaceuticals, Inc. Hydroxy substituted amides for the treatment of alzheimer's disease
AU2002359376B2 (en) 2001-11-08 2008-01-10 Elan Pharmaceuticals, Inc. N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
ATE359995T1 (de) * 2001-11-19 2007-05-15 Elan Pharm Inc Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
AU2002360508A1 (en) * 2001-12-06 2003-06-23 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
EA008389B1 (ru) * 2002-06-20 2007-04-27 Фармация Энд Апджон Компани Ллс Способ получения производных 5-(1,3-оксазол-2-ил)бензойной кислоты
WO2004014843A1 (ja) * 2002-08-09 2004-02-19 Takeda Chemical Industries, Ltd. 置換アミノ化合物およびその用途
CA2497979A1 (en) * 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
EP1537072A1 (en) * 2002-09-10 2005-06-08 Pharmacia & Upjohn Company LLC Substituted aminoethers for the treatment of alzheimer s disease
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
EP1542964A2 (en) * 2002-09-27 2005-06-22 Elan Pharmaceuticals, Inc. Compounds for the treatment of alzheimer's disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
ATE443043T1 (de) * 2002-11-12 2009-10-15 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
CA2507484A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
JP4559230B2 (ja) * 2002-11-28 2010-10-06 スベン ライフ サイエンシズ リミティド セロトニン受容体に対する親和性を有する新規ｎ−アリールスルホニル−３−置換されたインドール、その調製方法、それを含有する医薬組成物
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
TW200512195A (en) * 2003-04-21 2005-04-01 Elan Pharm Inc Benzamide 2-hydroxy-3-diaminoalkanes
WO2004094413A1 (en) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. Phenacyl 2-hydroxy-3-diaminoalkanes
AR045219A1 (es) 2003-08-08 2005-10-19 Pharmacopeia Inc Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico
WO2005016876A2 (en) 2003-08-08 2005-02-24 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
KR100793095B1 (ko) * 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
EP1673078B1 (en) 2003-10-03 2008-05-28 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
US20050255488A1 (en) * 2003-10-15 2005-11-17 Genaissance Pharmaceuticals NTRK1 genetic markers associated with age of onset of Alzheimer's Disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7550481B2 (en) 2003-12-19 2009-06-23 Merck & Co., Inc. Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease
JP2007528400A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
JP2007528402A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
WO2005087714A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
US20060128715A1 (en) * 2004-07-09 2006-06-15 Jennifer Sealy Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
WO2006010095A2 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
CA2574218A1 (en) 2004-07-22 2006-02-09 Schering Corporation Substituted amide beta secretase inhibitors
CA2575340A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
AU2005286844A1 (en) * 2004-09-17 2006-03-30 Comentis, Inc Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
US8178077B2 (en) 2004-10-19 2012-05-15 Reverse Proteomics Research Institute Co., Ltd. Drug development target protein and target gene, and method of screening
US7745470B2 (en) 2005-03-10 2010-06-29 Bristol-Myers Squibb Company Isophthalates as beta-secretase inhibitors
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
CN101198583A (zh) * 2005-04-08 2008-06-11 科门蒂斯公司 抑制β-分泌酶(SECRETASE)活性的化合物及其使用方法
NZ562314A (en) * 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
WO2006138265A2 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
EP1910317B1 (en) * 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
US7476764B2 (en) * 2005-08-04 2009-01-13 Bristol-Myers Squibb Company Phenylcarboxyamides as beta-secretase inhibitors
JPWO2007020888A1 (ja) 2005-08-12 2009-02-26 武田薬品工業株式会社 脳・神経細胞保護剤および睡眠障害治療薬
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007110727A2 (en) * 2006-03-27 2007-10-04 Pfizer Products Inc. Amide stabilized hydroxyethylamines
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
EP2066884B1 (fr) * 2006-09-22 2011-08-24 Renault Trucks Circuit de refroidissement d'un moteur thermique de vehicule automobile
JP2010522691A (ja) * 2006-11-23 2010-07-08 ノバルティス アーゲー ２−ヒドロキシ−１，３−ジアミノプロパン誘導体
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
CN101348456B (zh) * 2007-07-17 2011-05-11 中国科学院上海药物研究所 苄基哌啶类化合物及其制备方法和用途
US20100286145A1 (en) * 2007-07-26 2010-11-11 Comentis, Inc. Isophthalamide derivatives inhibiting beta-secretase activity
JP5055432B2 (ja) 2007-09-24 2012-10-24 コメンティス，インコーポレーテッド 治療のためのβ−セクレターゼ阻害剤としての（３−ヒドロキシ−４−アミノブタン−２−イル）−３−（２−チアゾール−２−イル−ピロリジン−１−カルボニル）ベンズアミド誘導体及び関連する化合物
WO2009129532A1 (en) * 2008-04-18 2009-10-22 University Of Connecticut Compounds for lysosomal modulation and methods of use
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
WO2010107384A1 (en) * 2009-03-19 2010-09-23 Medivir Ab Aspartyl protease inhibitors
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
EP2643299B1 (en) 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
CN102558157B (zh) * 2010-12-20 2014-04-30 中国科学院上海药物研究所 羟乙基三唑类化合物或氨乙基三唑类化合物及其制备方法和用途
CN103275070A (zh) * 2013-05-10 2013-09-04 郑彪 调节单核细胞增殖的四环化合物及其应用
CN106748892B (zh) * 2017-01-18 2018-09-18 四川大学 靶向自噬激动剂及其在神经退行性疾病治疗药物中的应用
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN108530319A (zh) * 2018-05-17 2018-09-14 辽宁凯莱英医药化学有限公司 肟类化合物及腈类化合物连续合成的方法
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1599907A (en) 1977-04-26 1981-10-07 Glaxo Lab Ltd Isoindolines
JPS5753564Y2 (es) 1977-06-01 1982-11-19
CH624011A5 (es) 1977-08-05 1981-07-15 Battelle Memorial Institute
FR2416008A1 (fr) 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4668770A (en) 1982-12-27 1987-05-26 Merck & Co., Inc. Renin inhibitory tripeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4474778A (en) 1983-11-09 1984-10-02 E. R. Squibb & Sons, Inc. Lactam containing compounds, their pharmaceutical compositions and method of use
US4512988A (en) 1984-03-01 1985-04-23 E. R. Squibb & Sons, Inc. Acylamino oxo or hydroxy substituted alkylamino thiazines and thiazepines
US4636491A (en) 1984-03-27 1987-01-13 Merck & Co., Inc. Renin inhibitory peptides having improved solubility
US4604402A (en) * 1984-03-30 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxy substituted ureido amino and imino acids
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPH0662529B2 (ja) 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
US4880781A (en) 1984-08-06 1989-11-14 The Upjohn Company Renin inhibitory peptides containing an N-alkyl-histidine moiety
JPS6150912A (ja) 1984-08-16 1986-03-13 Shionogi & Co Ltd リポソ−ム製剤の製造法
US4814270A (en) 1984-09-13 1989-03-21 Becton Dickinson And Company Production of loaded vesicles
US4749792A (en) 1984-09-26 1988-06-07 E. R. Squibb & Sons, Inc. Diamino ketones and alcohols as analgesic agents
US4616088A (en) 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4665193A (en) 1984-12-14 1987-05-12 E. R. Squibb & Sons, Inc. Amino acid ester renin inhibitors
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4753788A (en) 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
CA1290097C (en) 1985-07-24 1991-10-01 Merck & Co., Inc. Peptide enzyme inhibitors
US4729985A (en) 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
US5175281A (en) 1985-09-12 1992-12-29 The Upjohn Company Pharmaceutically active pyrimidinylpiperazinylsterioids
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987002986A1 (en) 1985-11-15 1987-05-21 The Upjohn Company Novel renin inhibiting polypeptide analogs containing s-aryl-d- or l- or dl-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
EP0258289A4 (en) 1986-01-16 1991-01-02 Joseph Dellaria Peptide analogs
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
DE3610593A1 (de) 1986-03-29 1987-10-01 Hoechst Ag Substituierte 4-amino-3-hydroxybuttersaeure-derivate verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
EP0264106B1 (en) 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
ES2062988T3 (es) 1986-12-19 1995-01-01 Sankyo Co Nuevos oligopeptidos inhibidores de la renina, su preparacion y su uso.
US5250565A (en) 1987-02-10 1993-10-05 Abbott Laboratories Indole-,benzofuran-,and benzothiophene-containing lipoxygenase-inhibiting compounds
DE3721855A1 (de) 1987-03-12 1988-09-22 Merck Patent Gmbh Aminosaeurederivate
BE1002213A5 (fr) 1987-04-23 1990-10-16 Sandoz Sa Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments.
JPH02504143A (ja) 1987-06-29 1990-11-29 ジ・アップジョン・カンパニー リンゴ酸誘導体含有レニン抑制ペプチド
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
JPH02504509A (ja) 1987-08-07 1990-12-20 ジ・アップジョン・カンパニー 非ペプチド結合を有するレニン抑制ペプチド
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
GB8728561D0 (en) 1987-12-07 1988-01-13 Glaxo Group Ltd Chemical compounds
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
IL89900A0 (en) 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
GB8927915D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
DE3941235A1 (de) 1989-12-14 1991-06-20 Bayer Ag Neue peptide, ihre herstellung und ihre verwendung in arzneimitteln
DE4001236A1 (de) 1990-01-18 1991-07-25 Bayer Ag Neue peptide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel, insbesondere als arzneimittel gegen retroviren
DE4003575A1 (de) 1990-02-07 1991-08-08 Bayer Ag Retroisostere dipeptide, verfahren zur herstellung und ihre verwendung als renininhibitoren in arzneimitteln
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
ES2217250T3 (es) 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
US5912410A (en) 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
JPH05508855A (ja) 1990-07-06 1993-12-09 スミスクライン・ビーチャム・コーポレイション レトロウイルスプロテアーゼ阻害剤
US5482947A (en) 1990-11-19 1996-01-09 Talley; John J. Retroviral protease inhibitors
US5510487A (en) 1990-11-19 1996-04-23 G.D. Searle & Co. Retroviral protease inhibitors
US5648511A (en) 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
ATE196759T1 (de) * 1990-11-19 2000-10-15 Monsanto Co Inhibitoren retroviraler proteasen
ES2236682T5 (es) 1991-01-21 2011-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
JPH06506463A (ja) 1991-04-04 1994-07-21 ジ・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルスの治療に有用な化合物
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5753652A (en) 1991-07-03 1998-05-19 Novartis Corporation Antiretroviral hydrazine derivatives
IE922316A1 (en) 1991-07-17 1993-01-27 Smithkline Beecham Corp Retroviral protease inhibitors
US5516784A (en) 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU671093B2 (en) 1992-01-07 1996-08-15 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
EP0628035A4 (en) 1992-02-26 1995-03-29 Smithkline Beecham Corp RETROVIRAL PROTEASE INHIBITORS.
DE69300043T2 (de) 1992-03-13 1995-05-24 Bio Mega Boehringer Ingelheim Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer.
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5376542A (en) 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
RU2146668C1 (ru) 1992-08-25 2000-03-20 Джи Ди Сирл энд Компани Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидное соединение, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз
US5760076A (en) 1992-08-25 1998-06-02 G.D Searle & Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US5830897A (en) 1992-08-27 1998-11-03 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5578606A (en) 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
EP0604182B1 (en) 1992-12-22 2000-10-11 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of Aids
MX9308025A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5461067A (en) 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds
NZ264143A (en) * 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
JPH07126286A (ja) 1993-11-05 1995-05-16 Yamanouchi Pharmaceut Co Ltd 新規なペプチド誘導体
WO1995018971A1 (en) * 1994-01-11 1995-07-13 Affymax Technologies N.V. Methods for the solid phase synthesis of glycoconjugates
US5733882A (en) 1994-01-17 1998-03-31 Smithkline Beecham Corporation Retroviral protease inhibitors
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5475138A (en) 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
DK0708085T3 (da) 1994-10-19 2002-11-11 Novartis Ag Antivirale ethere af aspartatproteasesubstrat-isostere
US5492910A (en) * 1994-11-17 1996-02-20 Bristol-Myers Squibb Co. Retrocarbamate protease inhibitors
US6001813A (en) 1994-11-21 1999-12-14 Cortech Inc. Val-pro containing α-keto oxadiazoles as serine protease inhibitors
AUPM982594A0 (en) 1994-12-02 1995-01-05 University Of Queensland, The HIV protease inhibitors
US5481011A (en) 1994-12-13 1996-01-02 Bristol-Myers Squibb Company Process for preparing N-protected amino acid α-halomethyl ketones and alcohols from N-protected amino acid esters
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5831117A (en) 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
CA2210889C (en) 1995-01-20 2007-08-28 G.D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
ID18218A (id) 1995-01-27 1998-03-19 Novo Nordisk As Senyawa dengan sifat-sifat pelepas hormon pertumbuhan
US5545640A (en) 1995-04-04 1996-08-13 Bio-Mega/Boehringer Ingeleheim Research Inc. Protease inhibiting succinic acid derivatives
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US5886046A (en) 1996-01-19 1999-03-23 The Trustees Of The University Of Pennsylvania Dicarbonyl-containing compounds
US5849691A (en) 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
CA2251066A1 (en) 1996-05-07 1997-11-13 Boehringer Ingelheim Pharmaceuticals, Inc. Process for preparing oxiranemethanamine derivatives
US5922770A (en) 1996-07-22 1999-07-13 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
WO1998022597A2 (en) 1996-11-20 1998-05-28 Oklahoma Medical Research Foundation Cloning and characterization of napsin, an aspartic protease
US6153652A (en) 1996-11-22 2000-11-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6127556A (en) 1996-12-31 2000-10-03 G. D. Searle & Co. Epoxide formation by continuous in-situ synthesis process
EP0958293B1 (en) 1997-02-04 2005-01-19 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998038167A1 (en) 1997-02-26 1998-09-03 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
US6221670B1 (en) 1997-03-21 2001-04-24 Scios Inc. Methods to identify β-amyloid reducing agents
IL132630A0 (en) * 1997-05-08 2001-03-19 Smithkline Beecham Corp Protease inhibitors
US5962506A (en) 1997-07-07 1999-10-05 Pharmacopeia, Inc. Glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases
DE69943314D1 (de) 1998-02-12 2011-05-12 Kapil N Bhalla Sphingolipid-derivate und verfahren zu deren verwendung
DE19817461A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
PT1086076E (pt) 1998-06-19 2005-05-31 Vertex Pharma Inibidores de sulfonamida de aspartil protease
WO2000003819A1 (en) 1998-07-17 2000-01-27 The Penn State Research Foundation Full form roll finishing technique
PL205294B1 (pl) 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
GB2364059B (en) 1999-02-10 2004-01-14 Elan Pharm Inc Beta-Secretase enzyme compositions and methods
JP2002539260A (ja) 1999-03-24 2002-11-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アスパルチルプロテアーゼインヒビターを使用して神経変性障害を処置する方法
JP2002541801A (ja) 1999-04-09 2002-12-10 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４８個のヒト分泌タンパク質
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
JP2003502342A (ja) 1999-06-15 2003-01-21 エラン ファーマスーティカルズ インコーポレイテッド ベータ−セクレターゼのスタチン誘導テトラペプチド阻害剤
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
WO2001010387A2 (en) 1999-08-09 2001-02-15 Vanderbilt University Antiviral therapy use of p-glycoprotein modulators
CA2377221A1 (en) 1999-09-13 2001-03-22 Bristol-Myers Squibb Pharma Company Hydroxyalkanoyl aminolactams and related structures as inhibitors of a.beta. protein production
WO2001023533A2 (en) 1999-09-23 2001-04-05 Pharmacia & Upjohn Company Alzheimer's disease secretase, app substrates therefor, and uses therefor
GB9924957D0 (en) 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
CA2395240A1 (en) 2000-01-13 2001-07-19 Genset S.A. Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
JP2004502664A (ja) 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
US20030096864A1 (en) 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease

Also Published As

Publication number Publication date
US20020128255A1 (en) 2002-09-12
EA200201247A1 (ru) 2003-10-30
UY26813A1 (es) 2002-01-31
HUP0303037A2 (hu) 2004-03-01
HU0303037D0 (en) 2003-11-28
WO2002002512A2 (en) 2002-01-10
NO20026199L (no) 2003-02-21
KR20030058960A (ko) 2003-07-07
EE200200716A (et) 2004-08-16
MXPA02012608A (es) 2003-05-14
EA007337B1 (ru) 2006-08-25
EP1353898A2 (en) 2003-10-22
JP2004502669A (ja) 2004-01-29
BR0112000A (pt) 2003-06-03
CA2410651A1 (en) 2002-01-10
NZ547529A (en) 2008-04-30
CN100366605C (zh) 2008-02-06
PE20020276A1 (es) 2002-04-06
NZ538542A (en) 2006-09-29
US7214715B2 (en) 2007-05-08
NO20026199D0 (no) 2002-12-23
HUP0303037A3 (en) 2006-02-28
AU2001273137A1 (en) 2002-01-14
WO2002002512A3 (en) 2003-08-21
NZ522899A (en) 2005-06-24
IL153214A0 (en) 2003-07-06
PL359864A1 (en) 2004-09-06
CZ20024194A3 (cs) 2004-01-14
SK18442002A3 (sk) 2004-07-07
CN1447789A (zh) 2003-10-08

Similar Documents

Publication Publication Date Title
AR031852A1 (es) Compuestos para tratar enfermedad de alzheimer
AR039555A1 (es) Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano
ATE520695T1 (de) Substituierte rylenderivate
PE20081775A1 (es) Compuestos macrociclicos como inhibidores del factor viia
CO5570669A2 (es) Pirazolopirimidinas como agentes terapeuticos
ES2539696T3 (es) 1,3-Tiazepinas condensadas con ciclopropilo, como inhibidores de BACE 1 y / ó BACE 2
AR061946A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas, su preparacion y composiciones farmaceuticas
GT200200224A (es) Benzamida, heteroarilamida y amidas inversas
HUP0104195A2 (hu) D vitamin analógok, előállításuk, hatóanyagként ilyen vegyületeket tartalmazó gyógyszer-kozmetikai készítmények
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
ECSP11010838A (es) Derivados de benzazepina y sus usos como antagonistas de histamina h3
ES2571327T3 (es) Composiciones plaguicidas
HRP20080024T3 (hr) Derivati alkilpiperazinskih i alkilhomopiperazinskih karboksilata, njihovo dobivanje i njihova upotreba kao inhibitori enzima faah
ES2175919T3 (es) Derivados del camptothecin con actividad antitumoral.
AR044178A1 (es) Derivados de piperidinil- y piperazinil-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
CO5550398A2 (es) 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos
CO5590960A2 (es) Derivados de azaindolilalquilamina como ligandos de 5- hidroxitriptamina-6
NO20072198L (no) Korrosjons- og gasshydratinhibitorer med foroket biologisk nedbrytbarhet og redusert toksisitet
DK1585493T3 (da) Triazinderivater som UV-absorbenter
ATE501103T1 (de) Organische verbindungen
Xiong et al. Synthesis, crystallographic characterization, and potential application of fullerene anisole derivatives as nitrocellulose stabilizer
EA200971060A1 (ru) Гетероариламидные пиримидоновые производные
AR094123A1 (es) Compuesto triciclicos
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
ATE490986T1 (de) Polymer, vernetztes polymer, zusammensetzung für ein feststoffpolymer-elektrolyt, feststoffpolymer-elektrolyt und klebstoffzusammensetzung

Legal Events

Date Code Title Description
FB Suspension of granting procedure